Abstract library

521 results for "poorly differentiated carcinomas".
#268 Temozolomide as 2.-3. line Treatment of Patients with Poorly Differentiated Neuroendocrine Carcinomas
Introduction: Knowledge of the clinical efficacy of treatment beyond first line of poorly differentiated neuroendocrine carcinomas (PDEC) is sparse. Temozolomide (TMZ) has shown effect in well-differentiated NET.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: M.D. Ingrid Holst Olsen
#602 Antitumoral Effect of Everolimus in Preclinical Models of Poorly Differentiated Neuroendocrine Carcinomas
Introduction: For the small and large cells poorly differentiated neuroendocrine carcinomas (PDNECs) emergency treatment remains the combination cisplatin/etoposide. However, recent studies suggest that targeted therapies could be a therapeutic option for this group of highly aggressive carcinomas.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Colette Roche
Authors: Bollard J, Couderc C, Blanc M, Poncet G, ...
#2248 High Grade (G3) Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: Should the New WHO Classification Apply to All?
Introduction: Grade 3 (G3) neuroendocrine neoplasms (NEN), arising from the gastro-entero-pancreatic system (GEP), are classified according to WHO 2010 and defined as having a Ki67 of > 20%. However this groups together G3 well differentiated neuroendocrine tumours (WD-NET) with poorly differentiated neuroendocrine carcinomas (PD-NEC). Recently, WHO have proposed a new classification for pancreatic NEN, with sub-division into G3 WD-NET and G3 PD-NEC
Conference: 15th Annual ENETS conference (2018)
Category: Pathology - grading, staging
Presenting Author: Dr Dalvinder Mandair
Authors: Furnace M, Muller G, Rundell C, Shah R, ...
#384 A Pilot Study on the Immunohistochemical Expression of Chromogranin and/or Synaptophysin in Moderate to Poorly Differentiated Gastroenteropancreatic Carcinomas
Introduction: Recent advances in specific treatment for neuroendocrine tumors (NETs) prompted us to reinvestigate the old phenomenon of neuroendocrine differentiation in carcinomas of the GI tract which has previously been shown to carry no prognostic significance.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr tony W Shek
Authors: Shek T W, Lam W Y, Yao H, Tang V, ...
Keywords: NET, IHC
#1199 Tumor Infiltrating Lymphocytes and PD-L1 Expression Differ in Low and High Grade Neuroendocrine Tumors
Introduction: Although much progress has been made in the past 2-3 years in terms of understanding signaling pathways in gastroenteropancreatic neuroendocrine tumors (GEP-NENs), approved treatment options are still limited. Cancer Immunotherapy has been announced as the breakthrough of the year in 2013 and might become an integral part of the clinical management strategy for solid tumors including GEP-NENs. Therefore, to develop immunotherapeutic strategies against NENs we need to know which immune escape mechanisms are relevant in high and low grade NEC/NENs.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: PD Dr. Patricia Grabowski
#42 Chemotherapy in the Treatment of Progressive, Undifferentiated Neuroendocrine Carcinomas: a Single-Center Experience.
Introduction: Treatment of poorly differentiated neuroendocrine tumors (NET) usually includes chemotherapeutic intervention. However, both the rarity and the heterogeneity of the disease have led to relatively few clinical trials. This study evaluated the outcome of two chemotherapy regimens in patients suffering from undifferentiated and histologically confirmed NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Timo Deutschbein
#507 Are all Metastatic Grade 3 WHO 2010 Neuroendocrine Carcinoma Poorly Differentiated?
Introduction: The WHO classification 2010 for neuroendocrine tumors (NET) defines poorly differentiated neuroendocrine carcinomas (NEC) as grade 3 (G3) according to mitoses> 20/10 HPF and/or Ki-67>20%.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Fritz-Line Vélayoudom-Céphise
#2257 Poorly Differentiated Neuroendocrine Carcinomas of the Colon: A Clinicopathological Study
Introduction: Neuroendocrine carcinomas (NEC) of the colon and rectum are aggressive and rare tumours. The Digestive Tract WHO classification 2010 defines the entity of large cell NEC (LCNEC) in contrast to small cell NEC (SCNEC).
Conference: 15th Annual ENETS conference (2018)
Category: Pathology - grading, staging
Presenting Author: Inga Boeck
Authors: Boeck I, Weihe E, Krieg A, Gabbert H E, ...
#1754 High-Grade Gastroenteropancreatic Neuroendocrine Tumors Compare to Neuroendocrine Carcinomas in 276 Patients
Introduction: The data compared well differentiated high-grade tumors with poorly differentiated neuroendocrine carcinoma (NEC) are very limited.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Liang Shang
Authors: Shang L, Li L P, ...
#311 Treatment and Prognosis of Patients with Poorly Differentiated Neuroendocrine Tumors
Introduction: Poorly differentiated neuroendocrine tumors (PDEC) represent less than 10% of all neuroendocrine tumors but have a poor prognosis.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Henning Grønbæk